Navigation Links
JAZZ PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2013 FINANCIAL RESULTS
Date:8/6/2013

are not historical facts.  These forward-looking statements are based on Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with maintaining and increasing sales of and revenue from Xyrem, such as the potential introduction of generic competition and changed or increased regulatory restrictions on or requirements with respect to Xyrem, as well as similar risks related to effectively commercializing the company's other marketed products, including Erwinaze and Prialt; protecting and expanding the company's intellectual property rights; obtaining appropriate pricing and reimbursement for the company's products in an increasingly challenging environment; ongoing regulation and oversight by U.S. and non-U.S. regulatory agencies; dependence on key customers and sole source suppliers, including the risk that the company may not be able to timely resolve potential product supply shortages and meet product demand; the difficulty and uncertainty of pharmaceutical product development and the uncertainty of clinical success and regulatory approval; the company's ability to identify and acquire, in-license or develop additional products or product candidates to grow its business; and possible restrictions on the company's ability and flexibility to pursue certain future opportunities as a result of its substantial outstanding debt obligations; as well as risks related to future opportunities and plans, including the uncertainty of expected future financial performance and results; and those other risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No
'/>"/>
SOURCE Jazz Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Cumberland Pharmaceuticals Reports Second Quarter Financial Results
2. Inovio Pharmaceuticals Responds to Market Activity
3. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
4. Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Bausch + Lomb
5. Avanir Pharmaceuticals to Participate in Two Conferences in August
6. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
7. AcelRx Pharmaceuticals to Present at Canaccord Genuity 33rd Annual Growth Conference
8. Isis Pharmaceuticals Reports Data From a Phase 2 Study of Isis-CRP Rx in Patients with Rheumatoid Arthritis
9. Intercept Pharmaceuticals to Present at the Wedbush Securities Life Sciences Management Access Conference
10. GW Pharmaceuticals Announces Results of MS Spasticity Study Confirming Sativex Has No Long-Term Negative Effect on Cognition
11. GW Pharmaceuticals plc Reports 2013 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/15/2014)... Jan. 15, 2014  Zafgen, Inc., a leading biopharmaceutical ... severely obese patients, today announced initial results from ... inhibitor of methionine aminopeptidase 2 (MetAP2), in patients ... genetic obesity.  These results showed improvements in body ...
(Date:1/14/2014)... FRAMINGHAM, Mass. , Jan. 14, 2014 ... a leading innovator of less invasive, miniaturized circulatory support ... failure, today announced that it expects revenues for the ... bringing expected full-year 2013 revenues to approximately $208 million. ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... For Pfizer, a key success factor in bringing ... the condition that the drug was designed to treat. ... shift the nomenclature for the condition from "impotence" (with ... dysfunction" (more clinical-sounding) to "ED" (casual and conversationally appropriate). ...
... At MEDRAD, Inc., community outreach is a celebrated ... Day of Caring, a company-sponsored event where employees ... volunteering in their communities. (Logo: ... 1000 MEDRAD employees will participate in the event ...
Cached Medicine Technology:Using Internal Communications to Help Build a Credible External Message Regarding New Pharmaceutical Products 2MEDRAD Employees Demonstrate Longstanding Commitment to Community 2MEDRAD Employees Demonstrate Longstanding Commitment to Community 3
(Date:7/10/2014)... Thompson HealthDay Reporter THURSDAY, ... wars that break out regularly between outspoken celebrities or loudmouth ... own relationship, a new study suggests. High amounts of ... if the couple is in a long-term relationship, according to ... In turn, that friction can lead to cheating and breakups, ...
(Date:7/10/2014)... More than 200 experts on aggression, who research issues ... attend the 21st World Meeting of the International Society ... Hotel, July 15-19. , Georgia State University is hosting ... year on alternating continents. , "We are excited to ... different countries, which will help produce fresh ideas about ...
(Date:7/10/2014)... infant seemingly cured of HIV that was reported as a ... The New England Journal of Medicine last fallnow ... of not taking antiretroviral therapy without evidence of virus, according ... case. , "Certainly, this is a disappointing turn ... in the child,s care, and the HIV/AIDS research community," said ...
(Date:7/10/2014)... The benefits of medical imaging far outweigh the ... Right Way, with The Right Radiation Dose. However, overuse ... Mayo Clinic is leading a collaborative effort to ensure ... published online in the Journal of Patient Safety ... Joint Commission, the Intersociety Accreditation Commission, and the Centers ...
(Date:7/10/2014)... brain operates much the same whether active or at ... understanding of schizophrenia, bipolar disorder and other serious mental ... , In newly published research in the journal ... Center for Molecular and Behavioral Neuroscience, determined that the ... basically the same as that of a person performing ...
Breaking Medicine News(10 mins):Health News:Are You Tweeting Your Marriage Away? 2Health News:Are You Tweeting Your Marriage Away? 3Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3Health News:'Mississippi Baby' now has detectable HIV, researchers find 2Health News:'Mississippi Baby' now has detectable HIV, researchers find 3Health News:Mayo Clinic calls for standardization of safe imaging protocols for children 2Health News:Working to loosen the grip of severe mental illness 2
... June 30 LifeSecure Insurance Company,(LifeSecure), a wholly-owned ... announced the executive appointment of Ron Hagen to ... sales executive with extensive knowledge of,the long term ... was,regional sales vice president, long term care sales ...
... Mesothelioma Center as a way for victims, or the ... get help,very honest advice & tailor made assistance at ... According to Americas Watchdog, "watching what happened to a ... help all Mesothelioma victims, with the best possible free ...
... in newborns undergoing painful procedures should be limited ... newborn screening test but not for intramuscular injections, ... In this double-blind, randomized controlled trial of 240 ... that "sucrose reduced overall pain in newborns when ...
... how much physical activity children need to boost their health and ... study published ahead of print in the Archives of Disease ... and only one in eight girls manage the recommended weekly amounts. ... of 113 boys and 99 girls from 54 different schools, all ...
... The cognitive strategies humans use to regulate emotions can ... a team of New York University and Rutgers University ... recent issue of the journal Nature Neuroscience , ... influence decision making. , Previous research has demonstrated ...
... 25, 2008 marks a revolutionary day in history for anybody who cares ... almost tantamount to July 4th, Independence Day, for Lung Cancer. For the ... voice, thanks to Senators Chuck Hagel, Dianne Feinstein and the tireless work ... Lung Cancer Alliance. , ...
Cached Medicine News:Health News:The Mesothelioma Victims Center Offers Victims Of Asbestos Related Cancer & Their Loved Ones The Most Comprehensive Free Service Especially For US Navy Veterans 2Health News:The Mesothelioma Victims Center Offers Victims Of Asbestos Related Cancer & Their Loved Ones The Most Comprehensive Free Service Especially For US Navy Veterans 3Health News:UK and US guidelines on kids' physical activity levels need rethinking 2Health News:NYU, Rutgers study shows how using mental strategies can alter the brain's reward circuitry 2Health News:Senators Chuck Hagel and Dianne Feinstein Make Lung Cancer Matter 2Health News:Senators Chuck Hagel and Dianne Feinstein Make Lung Cancer Matter 3Health News:Senators Chuck Hagel and Dianne Feinstein Make Lung Cancer Matter 4
Inquire...
Inquire...
... Before TOPscan Dispensers used to only have two ... process the completed job at a wholesale lab, ... The alternative was to finish the order in ... additional offices required another edger, lens inventory, more ...
Inquire...
Medicine Products: